Your browser doesn't support javascript.
loading
HIF prolyl hydroxylase inhibitor FG-4497 enhances mouse hematopoietic stem cell mobilization via VEGFR2/KDR.
Bisht, Kavita; Brunck, Marion E; Matsumoto, Taichi; McGirr, Crystal; Nowlan, Bianca; Fleming, Whitney; Keech, Thomas; Magor, Graham; Perkins, Andrew C; Davies, Julie; Walkinshaw, Gail; Flippin, Lee; Winkler, Ingrid G; Levesque, Jean-Pierre.
Afiliação
  • Bisht K; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Brunck ME; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Matsumoto T; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • McGirr C; Faculty of Pharmacological Sciences, Fukuoka University, Fukuoka, Japan.
  • Nowlan B; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Fleming W; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Keech T; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Magor G; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Perkins AC; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Davies J; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Walkinshaw G; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
  • Flippin L; FibroGen, Inc., San Francisco, CA; and.
  • Winkler IG; FibroGen, Inc., San Francisco, CA; and.
  • Levesque JP; Cancer Care and Biology Program, Mater Research Institute-The University of Queensland, Translational Research Institute, Woolloongabba, QLD, Australia.
Blood Adv ; 3(3): 406-418, 2019 02 12.
Article em En | MEDLINE | ID: mdl-30733301
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mobilização de Células-Tronco Hematopoéticas / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Inibidores de Prolil-Hidrolase / Isoquinolinas Limite: Animals Idioma: En Revista: Blood Adv Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Mobilização de Células-Tronco Hematopoéticas / Receptor 2 de Fatores de Crescimento do Endotélio Vascular / Inibidores de Prolil-Hidrolase / Isoquinolinas Limite: Animals Idioma: En Revista: Blood Adv Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Austrália